Target
suPAR
1 abstract
Abstract
Soluble urokinase-type plasminogen activator receptor, suPAR, as a prognostic biomarker in advanced pancreatic cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Experimental Cancer Therapy Unit, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Copenhagen University Hospital, Herlev Gentofte Hospital,